| 标题 |
[求助补充材料]
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:The Lancet HIV 作者:Eric S Daar; Edwin DeJesus; Peter Ruane; Gordon Crofoot; Godson Oguchi; et al 出版日期:2018-07-01 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)